GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » Total Inventories

Albireo Pharma (Albireo Pharma) Total Inventories : $3.15 Mil (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Total Inventories?

Albireo Pharma's total inventories for the quarter that ended in Sep. 2022 was $3.15 Mil. Albireo Pharma's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $2.62 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Albireo Pharma's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $0.21.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Albireo Pharma's Days Inventory for the three months ended in Sep. 2022 was 391.02.

Inventory Turnover measures how fast the company turns over its inventory within a year. Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.23.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Albireo Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.27.


Albireo Pharma Total Inventories Historical Data

The historical data trend for Albireo Pharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Total Inventories Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.19

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.19 1.82 2.10 3.15

Albireo Pharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Albireo Pharma  (NAS:ALBO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Albireo Pharma's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is

Net-Net Working Capital Per Share (Q: Sep. 2022 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(222.476+0.75 * 2.029+0.5 * 3.149-221.151
-0-0)/20.6927
=0.21

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Albireo Pharma's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2022 )/Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=2.6225/0.612*365 / 4
=391.02

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2022 ) / Average Total Inventories (Q: Sep. 2022 )
=0.612 / 2.6225
=0.23

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Albireo Pharma's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=2.6225 / 9.832
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Albireo Pharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (Albireo Pharma) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Executives
Harford Simon N.r. officer: CFO and Treasurer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson officer: Chief Commercial Officer C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter officer: Chief Regulatory Officer C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson officer: Chief Operating Officer C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham officer: Chief Human Resources Officer 10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan officer: General Counsel C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson director 852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina director C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003